Response Biomedical Corporation was founded in 2000 to commercialize technology developed at Simon Fraser University. Designed to detect biological threats, the technology uses proprietary antibodies to identify minute amounts of infectious diseases and environmental toxins.Since 2005, the company has focused on delivering point-of-care testing solutions for cardiology, infectious diseases and environmental factors. The RAMP® platform is used to deliver quick and accurate results in a wide range of diagnostic settings, from hospitals and laboratories to home healthcare providers, both in Canada and abroad.
